Latorre-Rodriguez Andrés, Shacker Mark, Mohamed Hesham, Bremner Ross M, Mittal Sumeet K
St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Escuela de Medicina y Ciencias de la Salud, Bogota D.C., Colombia.
Obes Surg. 2025 May 28. doi: 10.1007/s11695-025-07932-3.
An increasing number of patients with a history of bariatric surgery and advanced respiratory disease are presenting for lung transplantation (LTx). We aimed to describe and compare LTx outcomes between recipients with prior bariatric surgery and a matched control group at a high-volume lung transplant center.
After IRB approval, we identified bilateral LTx recipients with a pre-LTx history of bariatric surgery (Roux-en-Y gastric bypass [RYGB], sleeve gastrectomy [SG], or laparoscopic adjustable gastric band [LAGB]). The institutional experience is reported as a case series. Furthermore, perioperative and mid-term transplant outcomes such primary graft dysfunction (PGD), antibody-mediated rejection (AMR), acute cellular rejection (ACR), chronic lung allograft dysfunction (CLAD)-free survival, and overall survival (OS) were compared to a 1-to-2 propensity score-matched control group.
Nine patients (median age: 65 years; 77.8% female) with a history of bariatric surgery (RYGB = 4, SG = 4, LAGB = 1) a median of 76 months before LTx were included. The median hospital length of stay (LOS) and ICU-LOS were similar to the control group (n = 18). Moreover, 1-, 2-, and 3-year OS in bariatric and control groups were similar (88.9%, 88.9%, and 66.7% vs. 100%, 86.7%, and 78%, respectively; p = 0.27). CLAD-free survival and rates of PGD, AMR, and ACR were also similar.
Prior bariatric surgery may not affect overall or CLAD-free survival after bilateral LTx. Bariatric surgery for obesity treatment in patients with advanced lung diseases may improve their LTx candidacy without compromising early and mid-term transplant outcomes.
越来越多有减肥手术史和晚期呼吸系统疾病的患者前来接受肺移植(LTx)。我们旨在描述并比较在一家大型肺移植中心,有减肥手术史的受者与匹配的对照组之间的肺移植结果。
经机构审查委员会(IRB)批准后,我们确定了有减肥手术史(Roux-en-Y胃旁路术[RYGB]、袖状胃切除术[SG]或腹腔镜可调节胃束带术[LAGB])的双侧肺移植受者。将机构经验作为病例系列报告。此外,将围手术期和中期移植结果,如原发性移植物功能障碍(PGD)、抗体介导的排斥反应(AMR)、急性细胞排斥反应(ACR)、无慢性肺移植功能障碍(CLAD)的生存率和总生存率(OS),与1:2倾向评分匹配的对照组进行比较。
纳入了9例有减肥手术史的患者(中位年龄:65岁;77.8%为女性),在肺移植前中位时间为76个月(RYGB = 4例,SG = 4例,LAGB = 1例)。中位住院时间(LOS)和重症监护病房住院时间(ICU-LOS)与对照组(n = 18)相似。此外,减肥手术组和对照组的1年、2年和3年总生存率相似(分别为88.9%、88.9%和66.7%,对照组为100%、86.7%和78%;p = 0.27)。无CLAD生存率以及PGD、AMR和ACR的发生率也相似。
既往减肥手术可能不会影响双侧肺移植后的总生存率或无CLAD生存率。对晚期肺部疾病患者进行减肥手术以治疗肥胖,可能会改善其肺移植候选资格,而不会影响早期和中期移植结果。